Compounded GLP-1s vs. brand-name drugs: what the evidence says
Quick answer
Semaglutide and tirzepatide are FDA-approved GLP-1 receptor agonists with robust phase 3 trial data supporting significant weight loss outcomes in adults with obesity or overweight plus comorbidities. Compounded versions of these molecules are not FDA-approved and have not been evaluated for bioequivalence, potency consistency, or sterility under the same regulatory standards. The legal permissibility of compounding these drugs depends entirely on their current FDA shortage designation status, which has changed significantly in 2024 and 2025.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What's this video probably claiming?
Based on the caption linking directly to the Obesity Action Coalition's position paper on compounded GLP-1 alternatives, this creator, who appears to be a physician practicing in Alabama and/or Texas, is likely weighing in on the FDA shortage debate around compounded semaglutide and tirzepatide. The video probably argues that compounded versions of these drugs represent a legitimate, accessible option for patients who can't afford or access brand-name Wegovy, Zepbound, or Mounjaro. The hashtag stack, heavy with brand names, suggests the creator is either defending compounded GLP-1s or explaining the regulatory tension around them. Physicians in states like Texas and Alabama have been particularly vocal on this topic as FDA shortage designations have shifted, affecting whether compounding pharmacies can legally produce these drugs at all. This is a genuinely complicated regulatory and clinical conversation, and the OAC paper is a real, credentialed document worth examining.
What does the science actually show?
The clinical evidence for semaglutide and tirzepatide as branded formulations is strong. The STEP 1 trial (Wilding et al., 2021, NEJM) showed 2.4 mg subcutaneous semaglutide producing around 14.9% mean body weight loss over 68 weeks versus 2.4% for placebo. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found tirzepatide at 15 mg achieving up to 22.5% body weight reduction over 72 weeks. These are large, well-controlled trials using pharmaceutical-grade compounds manufactured under strict GMP conditions. The problem is that compounded versions of these molecules have not been tested in equivalent trials. The FDA has been explicit: compounded drugs are not FDA-approved and have not undergone the same safety and efficacy review. Salt-form discrepancies, particularly semaglutide sodium versus semaglutide base, add a layer of uncertainty that the clinical data simply does not resolve.
Where does the social media noise diverge from clinical reality?
The loudest claim circulating on TikTok is that compounded semaglutide and tirzepatide are essentially the same drug at a lower price. That framing is misleading, and it matters clinically. The FDA issued a specific warning in 2023 noting that compounded drugs using semaglutide salts are not the same as the active ingredient in Ozempic or Wegovy. Independent testing by organizations like the US Pharmacopeia and reporting from outlets including STAT News have flagged variable potency and sterility concerns in compounded formulations from some 503A and 503B pharmacies. None of this means every compounded product is dangerous, but the blanket equivalency claim that floats across health TikTok ignores real manufacturing variance. Separately, the OAC position paper the creator links to does not endorse compounded GLP-1s as equivalent to brand-name drugs; it advocates for access and calls for clearer regulatory guidance, which is a meaningfully different position.